Given that povetacicept has demonstrated improved BAFF/APRIL inhibition with superior pharmacokinetic and pharmacodynamic effects compared to telitacicept and other WT TACI-Fc proteins in preclinical (15) and clinical settings (18), including in the EAMG studies described here, the enhanced TACI-Fc fusion protein povetacicept may achieve superior outcomes in B cell-mediated autoimmune diseases like MG. This evidence concerns the gene TNFSF13B and myasthenia gravis.